.jpg)
With biosimilar competition looming, Roche takes a hit with failure of high-dose Ocrevus
With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade and face competition from cheaper biosimilars, Roche is looking for ways to extend its exclusivity for the top-selling drug in the indication. But the Swiss company can check one potential solution off its list as a phase 3 trial of its high-dose version of Ocrevus in patients with relapsing multiple sclerosis (RMS) has failed to move the needle.
With its multiple sclerosis powerhouse Ocrevus expected to lose patent protection by the end of the decade and face competition from cheaper biosimilars, Roche is looking for ways to extend its exclusivity for the top-selling drug in the indication. But the Swiss company can check one potential solution off its list as a phase 3 trial of its high-dose version of Ocrevus in patients with relapsing multiple sclerosis (RMS) has failed to move the needle.
